Accelerating Genomic Adoption in Onco-Hematology: The MaxCare Program Experience

Date: May 14, 2026 - May 14, 2026
Type: Live Webinar
Location: LATAM
Areas of Interest: Blood Cancers

Real-world insights from Hospital Mário Penna

In this webinar, we explore how the MaxCare Program supported Hospital Mário Penna in implementing and adopting into routine two new NGS applications for the investigation of myeloid and lymphoid malignancies. The program empowered the local team to gain confidence in their results while assessing and establishing the analytical performance of the workflow.

Hospital Mário Penna shares their experience with SOPHiA GENETICS’ end-to-end implementation support, covering every step of the process—from strategic consultation and on-site training to data generation and analytical performance evaluation by the data science team, all tailored to the laboratory’s real-world context. The session concludes with the transition of these tests into routine practice, illustrated through two case studies: one in acute myeloid leukemia (AML) and the other in chronic lymphocytic leukemia (CLL).

Speakers:

Carolina Pereira de Souza Melo, PhD,
Researcher, Basic and Translational Oncology Research Laboratory, Instituto Mário Penna, Brazil

Gabrielle Martins Gonçalves, MSc,
SOPHiA GENETICS Implementation Scientist LATAM

Day: May 14th
Time: 11h BR/AR l 10h CL l 9h CO/PA l 8h MX/CR

Register

Email

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expresseda during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services